NOTE: By submitting this form and registering with us, you are providing us with permission to store your personal data and the record of your registration. In addition, registration with the Medical Independent includes granting consent for the delivery of that additional professional content and targeted ads, and the cookies required to deliver same. View our Privacy Policy and Cookie Notice for further details.
Don't have an account? Register
ADVERTISEMENT
ADVERTISEMENT
Pictured are Annabel Murphy (aged 8) who has cystic fibrosis with Prof Paul McNally, RCSI Associate Professor of Paediatrics, at the launch of a new €3 million study, led by the RCSI, to investigate the real-world effects of a new cystic fibrosis medication. Researchers at the RCSI University of Medicine and Health Sciences are leading the international research project, called RECOVER, to look at how a new triple combination cystic fibrosis drug, Kaftrio, will affect people in their day-to-day lives. The project has been awarded €2.85 million from the Cystic Fibrosis Foundation (US), €112,000 from the Cystic Fibrosis Trust (UK), and €100,000 from Cystic Fibrosis Ireland.
ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT
The public-only consultant contract (POCC) has led to greater “flexibility” in some service delivery, according to...
There is a lot of publicity given to the Volkswagen Golf, which is celebrating 50 years...
As older doctors retire, a new generation has arrived with different professional and personal priorities. Around...
Catherine Reily examines the growing pressures in laboratory medicine and the potential solutions,with a special focus...
ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT
Leave a Reply
You must be logged in to post a comment.